common.study.topics.clinical

Preventing Posttraumatic Joint contractuRes with Ketotifen 2

common.study.values.description

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) is a Phase III randomized, controlled, double blinded multicenter trial with 3 parallel groups (Ketotifen 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks) and a primary endpoint of elbow extension-flexion range of motion (ROM) arc at 12 weeks post-randomization.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Lactose Placebo

One capsule by mouth twice per day

Drug - Ketotifen Fumarate 2mg

2 mg tablets (over-encapsulated into one capsule) by mouth twice per day

Drug - Ketotifen Fumarate 5mg

5 mg tablets (over-encapsulated into one capsule) by mouth twice per day

participant.views.study.view.additional

participant.views.study.view.scientific-title

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

common.study.values.clinical-trial-id

NCT03582176

participant.views.study.view.id

eXDxge